Showing results (21-30 of 42) with videos related to
Sort By:
Pageof 5
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2020
Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementiaJonas Hannestad, Katie Koborsi, Vicki Klutzaritz, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2014
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeysOlivier Barret, Jonas Hannestad, David Alagille, et al.Brain, Behavior, and Immunity|July 16, 2013
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET studyJonas Hannestad, Nicole DellaGioia, Jean-Dominique Gallezot, et al.Synapse (New York, N.Y.)|April 24, 2020
Inverse changes in raphe and cortical 5-HT1B receptor availability after acute tryptophan depletion in healthy human subjectsStephen R Baldassarri, Eunkyung Park, Sjoerd J Finnema, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2015
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated FluorodeprenylSangram Nag, Patrik Fazio, Lutz Lehmann, et al.Biological Psychiatry|August 10, 2010
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivoJonas Hannestad, Jean-Dominique Gallezot, Beata Planeta-Wilson, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|August 10, 2017
Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humansSjoerd J Finnema, Nabeel B Nabulsi, Joël Mercier, et al.Journal of Alzheimer'S Disease : JAD|May 10, 2021
Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled TrialJonas Hannestad, Tiffanie Duclos, Whitney Chao, et al.Epilepsia|February 28, 2016
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatmentHenrik Klitgaard, Alain Matagne, Jean-Marie Nicolas, et al.Epilepsia|December 15, 2015
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionJean-Marie Nicolas, Jonas Hannestad, Daniel Holden, et al.Pageof 5